Exploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma
Abstract Cholangiocarcinoma (CCA) presents a formidable therapeutic challenge due to its extensive heterogeneity and plasticity, which inevitably lead to acquired resistance to current treatments. However, recent evidence suggests that acquired drug resistance is associated with a fitness cost resul...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMC
2024-11-01
|
| Collection: | Cancer Cell International |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s12935-024-03548-2 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|